227 related articles for article (PubMed ID: 16412213)
41. Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas.
Urosevic M; Fujii K; Calmels B; Laine E; Kobert N; Acres B; Dummer R
J Clin Invest; 2007 Oct; 117(10):2834-46. PubMed ID: 17823660
[TBL] [Abstract][Full Text] [Related]
42. Hyperplasia of hair follicles and other adnexal structures in cutaneous lymphoproliferative disorders: a study of 53 cases, including so-called pseudolymphomatous folliculitis and overt lymphomas.
Kazakov DV; Belousova IE; Kacerovska D; Sima R; Vanecek T; Vazmitel M; Pizinger K; Michal M
Am J Surg Pathol; 2008 Oct; 32(10):1468-78. PubMed ID: 18685486
[TBL] [Abstract][Full Text] [Related]
43. T-cell primary cutaneous lymphomas. A clinicopathological and immunohistochemical study.
Caruntu ID; Mardari V; Radulescu D; Chirana A; Cozma L; Taranu T; Dobrescu G
Pol J Pathol; 2007; 58(4):259-65. PubMed ID: 18459460
[TBL] [Abstract][Full Text] [Related]
44. Immunomodulators in the treatment of cutaneous lymphomas.
Dummer R
Expert Opin Biol Ther; 2002 Mar; 2(3):279-86. PubMed ID: 11890867
[TBL] [Abstract][Full Text] [Related]
45. Introduction: cutaneous T-cell lymphoma (CTCL)--classification, staging, and treatment options.
Bagot M
Dermatol Clin; 2008 Jan; 26 Suppl 1():3-12. PubMed ID: 18405180
[No Abstract] [Full Text] [Related]
46. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
Vidulich KA; Talpur R; Bassett RL; Duvic M
Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
[TBL] [Abstract][Full Text] [Related]
47. Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC).
Kempf W; Ostheeren-Michaelis S; Paulli M; Lucioni M; Wechsler J; Audring H; Assaf C; Rüdiger T; Willemze R; Meijer CJ; Berti E; Cerroni L; Santucci M; Hallermann C; Berneburg M; Chimenti S; Robson A; Marschalko M; Kazakov DV; Petrella T; Fraitag S; Carlotti A; Courville P; Laeng H; Knobler R; Golling P; Dummer R; Burg G;
Arch Dermatol; 2008 Dec; 144(12):1609-17. PubMed ID: 19075143
[TBL] [Abstract][Full Text] [Related]
48. In vivo reflectance confocal microscopy assessment of the therapeutic follow-up of cutaneous T-cell lymphomas causing scalp alopecia.
Ardigò M; El Shabrawi-Caelen L; Tosti A
Dermatol Ther; 2014; 27(4):248-51. PubMed ID: 24754326
[TBL] [Abstract][Full Text] [Related]
49. Treatment of cutaneous T-cell lymphoma with retinoids.
Zhang C; Duvic M
Dermatol Ther; 2006; 19(5):264-71. PubMed ID: 17014481
[TBL] [Abstract][Full Text] [Related]
50. Cutaneous T-cell lymphoma/leukemia.
Siegel RS; Kuzel TM
Curr Treat Options Oncol; 2000 Apr; 1(1):43-50. PubMed ID: 12057060
[TBL] [Abstract][Full Text] [Related]
51. Cutaneous T-cell lymphoid dyscrasia: a unifying term for idiopathic chronic dermatoses with persistent T-cell clones.
Guitart J; Magro C
Arch Dermatol; 2007 Jul; 143(7):921-32. PubMed ID: 17638739
[TBL] [Abstract][Full Text] [Related]
52. Graft-versus-lymphoma effect.
Richard C; Bermúdez A; Izu R
Br J Haematol; 2010 Apr; 149(2):166. PubMed ID: 20015300
[No Abstract] [Full Text] [Related]
53. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
Geskin L
Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
[TBL] [Abstract][Full Text] [Related]
54. Graft-versus-T-cell non-Hodgkin's lymphoma effect.
Hsiao LT; Chiou TJ; Wang WS; Chen PM
Int J Hematol; 2006 Apr; 83(3):193. PubMed ID: 16720545
[No Abstract] [Full Text] [Related]
55. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).
Guitart J
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S17-20. PubMed ID: 16516671
[TBL] [Abstract][Full Text] [Related]
56. The expression of MUM1 in cutaneous T-cell lymphoproliferative disorders.
Wasco MJ; Fullen D; Su L; Ma L
Hum Pathol; 2008 Apr; 39(4):557-63. PubMed ID: 18234282
[TBL] [Abstract][Full Text] [Related]
57. Primary cutaneous T-cell lymphoma expressing FOXP3: a case report supporting the existence of malignancies of regulatory T cells.
Marzano AV; Vezzoli P; Fanoni D; Venegoni L; Berti E
J Am Acad Dermatol; 2009 Aug; 61(2):348-55. PubMed ID: 19615546
[TBL] [Abstract][Full Text] [Related]
58. Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions.
Rubio-Gonzalez B; Zain J; Rosen ST; Querfeld C
Br J Haematol; 2017 Jan; 176(1):16-36. PubMed ID: 27782301
[TBL] [Abstract][Full Text] [Related]
59. Immunomodulators in the treatment of cutaneous lymphoma.
Rogalski C; Dummer R; Burg G
J Eur Acad Dermatol Venereol; 1999 Sep; 13(2):83-90. PubMed ID: 10568485
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids.
Stadler R; Kremer A
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S7-10. PubMed ID: 16516669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
